Harnessing the Power of Collaboration

ASH Clinical News spoke with Richard Pazdur, MD, director of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), about the scope of the new center and its efforts to accelerate...

Online Exclusives

Identifying Causes of Cardiomyopathy in Patients With Sickle Cell Anemia

Author’s Perspective Lead author Omar Niss, MD: “Diffuse myocardial fibrosis is a common finding and a newly recognized mechanism of heart disease in sickle cell...

FDA Calls for Manufacturer to Pull Opioid from the Market

The U.S. Food and Drug Administration (FDA) has called for Endo Pharmaceuticals to remove its reformulation of oxymorphone hydrochloride extended-release, Opana ER, because of...

News

From the Blood Journals

WIB_icon

Rates of Myeloid Neoplasms in Patients With Unexplained Cytopenias

Patients with unexplained cytopenias may never receive a definitive diagnosis, or may eventually be classified as having myelodysplastic syndromes (MDS, a myeloproliferative neoplasm ...
WIB_icon

Enoxaparin Increases Risk of Intracranial Hemorrhage in Patients With Glioma

Venous thromboembolism occurs in approximately one-third of patients with glioma, but the decision to treat patients with anticoagulation is complicated by the risk for...

Latest Videos

video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
video

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
video

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
video

Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas

Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...

On Location

Mixed Results in Trials of Momelotinib Versus Ruxolitinib for Myelofibrosis

The investigational JAK1/2 inhibitor momelotinib was active in the treatment of myelofibrosis (MF) in phase...

BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML

Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major...

Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy Is Safe, Effective in Older Patients With ALL

In February 2017, the U.S. Food and Drug Administration granted inotuzumab ozogamicin priority review for...

Early Results from CAR T-Cell Therapy Trial for Myeloma Show “Encouraging” Response Rates

In an ongoing, phase I trial of chimeric antigen receptor (CAR) T-cell therapy in patients...

Minimizing VTE Risk in Myeloma Patients Receiving Immunomodulators

Patients with myeloma who receive treatment with immunomodulatory drugs (IMIDs) such as lenalidomide and thalidomide...

Is Denosumab a Safer Alternative to Zoledronic Acid in Newly Diagnosed Myeloma?

Patients with multiple myeloma (MM) can experience osteolytic bone disease that is typically treated with...

Latest Headlines

Advertisement

ASH Directions

AML Matters Summit, ASH President Participates in LLS Panel Discussion, and more

AML Matters Summit Continues Across U.S. AML Matters is a free educational program designed to provide guidance to health-care professionals on the optimal diagnosis and...

Marching for Science, New Opportunities for International Collaboration, and more

Marching for Science The first March for Science, which took place Saturday, April 22, 2017, in more than 600 locations around the world, drew hundreds...

Sign up for our e-Newsletter!

Remembering Neil Abramson, MD, AACC Announces Clinical Chemistry Trainee Council Educational Initiative, and more

Remembering Neil Abramson, MD (1937-2017) Neil Abramson, MD, a hematologist/oncologist who served as a Blood Special Section Editor from 2008-2012, passed away at the age...

ASH 2017 Bridge Grant Awards, Hematologists Receive Stand Up To Cancer 2017 Innovative Research...

ASH Announces 2017 Bridge Awards The American Society of Hematology (ASH) announced the names of five investigators who have received the latest round of ASH...

ACS Announces Lane W. Adams Quality of Life Award Winners, 2017 Eric G. Neilson,...

ACS Announces Lane W. Adams Quality of Life Award Winners The ACS honored six cancer caregivers with the Lane W. Adams Quality of Life Award,...

Show Me the Money? Show Us the Data!

How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers? The merits and cautions of data sharing have long been a...

Uncommon Presentations, Uncommon Cancers

In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer. Have you read any hematology-related books recently? Let...

Agent Orange and Hematologic Malignancies: The Fog of War Still Hovers

More than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging...